United Arab Emirates

Population 2017: 9.4 million

### Tuberculosis Profile

#### Estimates of TB burden*, 2017

<table>
<thead>
<tr>
<th>Category</th>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>0.065 (0.038–0.1)</td>
<td>0.69 (0.4–1.1)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>&lt;0.01 (&lt;0.01–0.01)</td>
<td>0.01 (0.01–0.02)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>0.076 (0.065–0.088)</td>
<td>0.81 (0.69–0.93)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>&lt;0.01 (&lt;0.01–0.01)</td>
<td>0.08 (0.06–0.09)</td>
</tr>
<tr>
<td>Incidence (MDR/RR-TB)**</td>
<td>&lt;0.01 (&lt;0.01–0.01)</td>
<td>0.04 (0.02–0.07)</td>
</tr>
</tbody>
</table>

#### Estimated TB Incidence by age and sex (thousands)*, 2017

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Females</th>
<th>Males</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-14 years</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>&gt; 14 years</td>
<td>0.03</td>
<td>0.03</td>
<td>0.067</td>
</tr>
<tr>
<td>Total</td>
<td>0.034</td>
<td>0.042</td>
<td>0.067</td>
</tr>
</tbody>
</table>

#### TB Case Notifications, 2017

- Total cases notified: 70
- Total new and relapse: 66
- % tested with rapid diagnostics at time of diagnosis: 44%
- % with known HIV status: 89%
- % pulmonary: 74%
- % bacteriologically confirmed among pulmonary: 96%

#### Universal Health Coverage and Social Protection

- TB treatment coverage (notified/estimated incidence), 2017: 87% (75–100)

#### Estimated % of TB cases with MDR/RR-TB

- 3.7% (2–5.9)

#### Laboratory-confirmed cases

- MDR/RR-TB: 1

#### Patients started on treatment****

- MDR/RR-TB: 0

#### New and relapse success rate

- Treatment success rate (%): 88%

#### TB Preventive Treatment, 2017

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 11%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 37% (28–58)

#### TB Financing, 2018

- National TB budget (US$ millions)

---

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Generated: 2019-03-23